First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
about
Interventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for preventing oral mucositis for patients with cancer receiving treatmentClinical management of localized colon cancer with capecitabineRelationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study.Treatment of colorectal cancer in the elderlyReview of systemic therapies for locally advanced and metastatic rectal cancerManagement of locally advanced and metastatic colon cancer in elderly patientsEvaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidinesA candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMSDecision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.Oral drugs in the treatment of metastatic colorectal cancer.Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsCapecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trialPilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine.A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer.Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancerIdentification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analysesTargeting cancers in the gastrointestinal tract: role of capecitabineMaintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinomaNeoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancerCapecitabine in gastric cancer.A phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsPlacebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.Chemotherapy for colorectal cancer.Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study.Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reductionA randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials.Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumoursS-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysisAdjuvant therapy for rectal cancer--the transatlantic view.Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis.Phase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patientsPostoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer.Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies
P2860
Q24235217-33CFA8C9-6F1D-4EF9-8DE4-3FA5D02050DBQ24235482-CAF21400-3F1C-4697-BA38-78BF11773A3AQ24243046-880884CC-B086-40D1-850B-6510FC38D450Q24611758-79FE89AB-3E93-4D20-BBF4-21593E418CB6Q25257445-5E5E23C1-562F-4390-9D2B-93F8DF06BF1DQ26781457-4A041754-1121-4953-9C20-6351371CFFB7Q27021105-A2BB51C2-A4A9-44E8-971E-E873F899FB07Q27026129-E4515519-C4A6-4507-91E8-4F3BDD815143Q28534572-436D7770-5C79-444C-8D0D-3929821F8604Q28652720-2F10E5AD-3C3F-44F3-856F-5C5CDC672EC8Q30244769-CEAA58AC-96F4-486C-ACF5-65322D7B84B8Q30251387-49FD2833-F917-4BE0-87EA-A2CA9B46253EQ30913489-31103A47-21B4-498E-B70F-60F28033C7A8Q33361603-D4FCA873-E987-431B-B752-994F8D749729Q33370303-BE0821FD-DC2E-4FD8-A54D-B08DB5D59BECQ33420046-E04F8F22-5B71-42BA-9013-17FEF7C112FEQ33425826-18CF6DA1-E292-418E-9F43-D5FEE71501AEQ33620052-8997D9DC-4FB6-42B9-BB19-342AAFB093EFQ33825180-6B46CD2F-3D27-4DB9-8250-6CD9443AB701Q33916021-D8F1FFAF-2B35-427F-86B5-55CD30F46B18Q33967458-E40C9356-3259-47A3-A87D-E900FDFE77B0Q34006430-C3890FD1-C51E-4909-BEFD-A5C3753E2C84Q34202729-5464EED3-8A54-40C8-BE84-6C89AB4F08A7Q34236005-A72ED09E-9403-4717-B548-704F6ECA469CQ34334959-BA74018A-14B6-44F3-96DA-3AAA95BDD09CQ34488678-06E3D8F4-CDCE-4635-AF8E-FAB99AD6B2ACQ34494672-2A174692-1B6B-49D5-9BCC-FCD7581684C0Q34500981-FCCACB5F-BFB1-47EA-8EF0-D9E3486B3AC0Q34577462-555C6AD2-CA4F-4533-BEFF-0BECBB0B6773Q34609932-15B16EB4-8477-476B-AA07-13930FC7B2D7Q34632080-3EE95CEB-BA68-45BA-8916-29ADAF1C194BQ34639725-CDFAB9F0-125D-4FE6-9D84-30FA3E7CCF7EQ34746009-1FC452AE-4024-40B6-BC0A-9BBD3B6C3EBEQ35070531-3A0B5EC4-FBD8-401B-BF73-C5447EBD08E7Q35083334-FDA0C77D-0784-43E8-BCE1-42A536EE86DFQ35202155-6DF7C46C-20A4-4E01-940B-BB2668CD45DCQ35444531-E75553B7-99FD-4831-9579-F8EE9A5E41B4Q35482173-2E646F9C-2EBF-461F-9862-77C951102C74Q35542484-91F4AAFB-3A97-4EA7-AACF-CC767FA25674Q35615863-BCBE2CDA-DD84-4C51-8D8A-5AAF605223D9
P2860
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
First-line oral capecitabine t ...... ous 5-fluorouracil/leucovorin.
@en
First-line oral capecitabine t ...... ous 5-fluorouracil/leucovorin.
@en-gb
type
label
First-line oral capecitabine t ...... ous 5-fluorouracil/leucovorin.
@en
First-line oral capecitabine t ...... ous 5-fluorouracil/leucovorin.
@en-gb
prefLabel
First-line oral capecitabine t ...... ous 5-fluorouracil/leucovorin.
@en
First-line oral capecitabine t ...... ous 5-fluorouracil/leucovorin.
@en-gb
P2093
P356
P1433
P1476
First-line oral capecitabine t ...... ous 5-fluorouracil/leucovorin.
@en
P2093
B Osterwalder
Capecitabine Colorectal Cancer Study Group
E Van Cutsem
G Pérez-Manga
J Marshall
P304
P356
10.1093/ANNONC/MDF089
P577
2002-04-01T00:00:00Z